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CHAPTER I 
INTRODUCTION 
Successful control of arthropods and the diseases they vector 
are often difficult due to the treatment regimen required and the 
severity of the infection or disease epidemiology. Current recommenda-
tions for prophylaxis and control of arthropods and diseases of cattle 
are based on the application of an insecticide or acaricide to the 
target organism and the administration of biologically active compounds 
via parenteral dosages, feed throughs,water additives and the use of 
salt or mineral blocks. These methods provide effective control only 
when strict and periodic programs are implemented and intensely managed. 
The effectiveness of these treatments are generally short-lived and 
require repeated applications. With an increasing emphasis on a 
complete herd health program commercial application of these methods 
have limitations under rangela11d and some feed-lot conditions. Daily 
treatments prove laborious, time-consuming and expensive. Also, when 
agents are introduced via ratii>ns, water and other vehicles, intake is 
variable and inadequately monitored. The continual trend towards 
increased production in the cattle industry, arthropod and disease 
control procedures as currently used, may provide protection for live-
stock but the producer absorbs the increasing cost of maintaining such 
a program. From this standpoint, there is an obvious need for a new and 
improved economical method for arthropod and disease p~ophylaxis and 
control. 
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One approach to minimize daily management costs through disease and 
parasite prophylaxis would be to administer therapeutics through a 
sustained-release system employing ear tags, implants, boluses, etc. 
Sustained-release Systems 
Interest in controlled-release devices has resulted in new 
procedures for animal health care and production. Growth stimulants 
have been administered via implantation of a biologically active pellet 
beneath the skin of the ear with sufficient levels being offered for 
a 100-120 day period. Insecticide-impregnated ear tags have been 
developed for ectoparasite control on livestock (Gladney 1976; 
Ahrens et al. 1977). Veterinary boluses have been designed to provide 
small amounts of vitamins, trace elements, and pesticides to ruminants. 
As a result of successful controlled-release devices for animal health 
and production, new procedures by which administration of acaricides 
and chemotherapeutic agents can be offered to ruminants over a prolonged 
period of time have resulted. 
Early observations on the bolus technique using crude associated 
technology by Dewey et al. (HS8) provided cobalt in small amounts to 
grazing sheep on cobalt deficient pastures in Australia via a 11 cobalt 
pellet 11 delivering therapeutic levels for 100 days. Pellets prepared 
by compressing trace elements with various binders such as china clay 
and polyvinyl acetate have also been developed and retained within the 
rumen in excess of l year (Marston 1962). In subsequent testing, 
Rednick and Tucker (1970) developed a bolus utilizing a sulfonamide 
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drug mixed with a binder and dense filler for sulfonamide administratioD 
to beef animals. 
Siegrist and Katz (1970) utilized a bolus to syncronize estrus in 
I 
cattle for artificial insemination. Their composition of an insoluble 
wax, a high-density metal derivative, a lubricant, and the therapeutic 
agent, provided a reliable controlled-release of the agent with a 
finite end point. Formulation was accomplished by preparing the 
composition in a liquid melt. More recently, Teel et al. (1978) 
investigated the feasibility of incorporating systemic pesticides for 
ectoparasite control in a sustained-release system and demonstrated that 
a 50 percent famphur systemic acaracide bolus offered effective control 
against two 3-host tick species for up to 60 days. Likewise, Hair et 
al. (1979) demonstrated the effectiveness of the same system against 
Boophilus ticks. The principal on which these devices operate was 
based on the retention of the boluses in the rumeno-reticular sac of 
the ruminant. Through normal peristaltic movements during rumination, 
the active ingredient was released through erosion, leaching or other 
means and was utilized systemically. 
Density has been found to be a primary factor in the success of 
these devices since bolus retention within the rumen was related to the 
specific gravity. Siegrist anj Katz (1970) in conducting experiments 
concerning minimum critical densities, found that wh;.le a density of 
1.9 g/cm3 is preferred, a density of 1.5 g/cm3 was minimal. Teel et al. 
(1979) demonstrated a direct relationship between bolus density and 
rumen retention. They found that the degradation rate was inversely 
proportional to the amount of pressure used to compress the boluses. 
They also found that hydrophobic binders produced the longest lasting 
boluses and that mixtures of candidate components could constitute the 
matrix base necessary to achieve the desired release rate. These 
authors provided insight into means of formulating a sustained-release 
system that has the potential to be effective in offering biologically 
active compounds to ruminants over an extended period of time. 
Effective administration was offered as long as blood levels were 
maintained without becoming toxic to the host. 
A prolonged-release formulation has several potential advantages 
compared to non-prolonged forms: better animal compliance, more 
constant blood levels resulting in shorter and fewer treatment periods 
and therefore, reduced cost. The usual parenteral or oral treatment 
regimen results in high peak blood levels which fall well below 
therapeutic concentrations before administration of the next dose. 
Studies have indicated that therapeutic levels must be above a minimum 
inhibitory concentration (MIC) for a specified period to eradicate 
an infection or disease and this action was relatively independent of 
whether the level was achieved by constant infusion or intermittent 
bolus dosing (Schneider et al. 1978). Since therapeutic levels may be 
below the MIC for significant periods after parenteral dosages, there 
may be unnecessary prolongation of treatment and consequently, 
excessive drug consumption. 
Vector-borne Anaplasmosis 
In certain circumstances a prolonged-release antibiotictreatment 
regimen may allow successful treatment of vector-borne bovine diseases 
such as anaplasmosis where continuous therapy is needed. Anaplasmosis 
4 
is an infectious, parasitic disease of cattle caused by the microorganism 
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Anaplasma marginale (Theiler). The disease is transmitted by arthropods 
either mechanically or biologically. Ticks have been established as 
efficient vectors of anaplasmosis since they are resistant to environ-
mental changes, are long-lived and can overwinter. Disease transmission 
occurs during the ingestion of the blood meal when the disease agents 
are passed via the bite. Although mechanical transmission has been 
shown to occur by bites of horseflies (Tabanus ~.),stable flies 
(Stomoxy sp. ), deer flies (Chrysop ~·) and horn flies (Haematobia sp. ), 
ticks appear to be primarily responsible for the continuation and 
biological transmission of anaplasmosis (Howell 1957, Dickmans 1950). 
A number of ticks have been found associated with cattle during out-
breaks of anaplasmosis. Dermacentor variabilis (Say) and Q. andersoni 
Stiles have been shown by laboratory and field studies to be important 
vectors of anaplasmosis in the United States (Anthony et al. 1964, 
Anthony and Roby 1962, Boynton et al. 1936, Kocan 1979). 
Although animals of all ages may be susceptible to anaplasmosis 
the severity of the disease is directly related to age. The syndrome 
in yearling cattle is usually sub-clinical and severe (frequently fatal) 
in older cattle (Blood and Herderson 1960; Ristic 1960). The disease 
may result in poor reproductiv:: ability, abortion, severe weight loss, 
decreased milk production, fe r, constipation, anemia, and sometimes 
death. These are accompanied uy icterus, inappetence, depression, 
dehydration, and labored respiration (Carricaburu 1957). 
It has been estimated that 50-100 thousand animals die of anaplas-
mosis each year with an annual economic loss of 100 million dollars 
(McCallon 1973). Although a vaccine is available and .effective 
chemotherapeutic agents are in use, treatment of anaplasmosis continues 
to be an important tool in the control of losses due to this disease. 
Christensen (1956) reported on several non-specific compounds such 
as sodium cacadylate, neoarspenamine, paludrine, aralen, aricyl, and 
other drugs were judged by the percent recovery of treated animals. In 
a report by Dykstra et al. (1948) most of the compounds were found to 
be of no value or of questionable value. 
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Tetracyclines are recognized as effective in prophylaxis and 
control of anaplasmosis and their action in suppressing the growth and 
multiplication of the causal agent has been described (Brock 1959). 
Miller et al. (1952) reported that the use of chlortetracycline and 
oxytetracyline halted the increase in anaplasma bodies when administered 
in the early phase of anaplasmosis infectivity. Foote and Wulf (1952) 
demonstrated that relatively large doses (27.5-47.5 g) of chlorte-
tracycline destroyed the infection in 3 cows. Later, it was reported 
by Pearson and Brock (1953) that dosages of 47.5 g only temporarily 
prevented transmission ability (up to 67 days) and did not destroy the 
infection. Scales et al. (1962) found that low-level feeding of 
tetracyclines slowly reduced the blood titers of anaplasmosis reactors 
., 
and thereby reduced their inf;,~,~tivity. Carrier status has been 
eliminated utilizing intraver .. us (I.V.) and intramuscular (I.M.) 
injections of tetracyclines f ' 10 consecutive days (Pearson et al. 
1957). 
In addition to the previous references there have been a number of 
reports indicating the value of tetracyclines used in the treatment of 
anaplasmosis. More recently, Magonigle et al. (1975) found that 
I.V. injections of oxytetracycline at 22 mg/kg for 5 consecutive days 
could eliminate the infectivity of anaplasma bodies. Results from Roby 
et al. (1978) showed that 2 I.M. injections of a new long-acting 
oxytetracycline formulation {L-200) 7 days apart would eliminate the 
carrier state from recently infected yearling cattle. 
Evidence suggest that the tetracyclines are capable of exerting 
an inhibitory effect on the anaplasma organism. Anaplasmosis varies 
greatly in severity, mortality, and symptoms and the treatment 
effectiveness depends on the following conditions: (1) age and condi-
tion of the animal infected; (2) animal resistance to the disease; 
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(3) animal ability to regenerate red blood cells; and (4) virulence of 
the specific agent. A corrmon error in evaluation of therapeutic agents 
is the number of spontaneous recoveries which misled observers to 
believe that a specific drug or procedure was effective. Another 
problem is that the animal infected may go undetected until the terminal 
phase of infection occurs. E~rly treatment is recognized as being 
most effective during early infectivity phases. 
With an increasing incidence of anaplasmosis in most of the plains 
and west coast states, the potential of a sustained-release system 
involves a need to develop chemotherapeutic formulations which are 
applicable throughout vector seasons and in difficult management situa-
tions. Current methods previously described have limitations. 
Antibiotic therapy when administered parenterally in its present formu-
lation, maintains effective blood concentrations for a reasonably short 
period of time. As in most cases, multiple injections are required 
to achieve the desired control, especially when the disease is in vary-
ing stages of development. These prolonged treatment periods are in 
conflict with most management practices. This, along with the expense 
of the drugs and labor necessary to implement such a program leads 
researchers to search for improved formulations which would enhance 
the effect of treatment and possibly reduce the length and number of 
treatments. Therefore, it is the scope of this manuscript to describe 
the investigations into the research and development of a sustained-
release oxytetracycline bolus for prophylaxis and control of anaplas-
mosis in bovine. The approach was 2-fold, including screening of 
candidate matrixes and compositions for compatibility with oxytetra-
cycline and bio-assay determinations for efficacy against vector-borne 
analplasmosis. 
CHAPTER II 
SCREENING OF CANDIDATE MATRIXES COMPATIBLE 
WITH OXYTETRACYCLINE 
Methods and Materials 
General Procedures 
------·--·--··----
Based on previous studies at the Oklahoma State University 
laboratory in the development of sustained-release boluses, considera-
tions in matrix formulation were based on a number of factors which 
included bolus size and density, utilization of non-toxic matrix 
ingredients, desired release rates, and bolus longevity. In initial 
testing of candidate matrixes to ascertain the feasibility of formu-
lating a long-termed sustained-release oxytetracycline bolus for use 
in bovine, grade hereford and angus heifers having an average weight 
of 364 kgs were fistulated for rumenal cannulas (Bar Diamond, Inc., 
Parma, Indiana). The aperture allowed for entry to the rumen on a 
bi-weekly basis for bolus retrieval and evaluation. After 10 days 
post-operative antibiotic therapy, the heifers were maintained on a 
cotton seed-hull based ration (Williams et al. 1977) under dry-lot 
conditions in order to minimize gain during the test period. Prior to 
administration, boluses in each animal were coded to monitor degrada-
tion of individual boluses. Bolus erosion and thus oxytetracycline 
released, was monitored by removing the boluses from the rumen, drying 
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them with a paper towel, weighing them on a digital electronic balance, 
and calculating release rates from bolus weight loss. Boluses were 
then reinserted to respective hosts. 
Oxytetracycline boluses were prepared using a matrix containing a 
highly-hydrophobic binder (carnauba wax), a high-density non-toxic 
metal derivative (barium sulfate), a polymer (polyethyleneglycol) to 
facilitate bolus degradation, and the active ingredient oxytetracycline. 
The matrix was prepared as described by Teel and Hair (1978), by melting 
the carnauba wax in a double boiler heated above 86°C for the purpose 
of combining the high-density barium sulfate and the polyethyleneglycol 
(PEG). The liquid melt was poured into aluminum trays to a thickness 
of 4 mm and allowed to cool to room temperature before being ground 
to a powder using a standard kitchen model blender. The matrix 
powder was screened through a U.S. standard 40 mesh sieve and then 
blended with the active ingredient, oxytetracycline. Appropriate 
aliquots of the final formulation (45 g) were hydraulically pressed(Soil 
Test, Inc.) to form a conventional veterinary bolus 7.6 by 2.25 cm with 
a mean density of 1.89 g/cm3. Since testing conducted by Siegrist 
and Katz (1970) reported that the rate of release of the therapeutic 
agent is inversely proportional, within limits, to the compression 
rates, bolus formulations were pressed between 492-632 kg/cm2 for 
proper cohesion and binding of particles. 
Varying Matrix Compositions 
Results from early pilot studies indicated that in order to· 
achieve a bolus with a high-specific gravity that would effectively 
deliver a desired therapeutic dose over a 45-60 day period, the proper 
components, rates of each, and sufficient compression were needed to 
accomplish such an objective. During these preliminary trials in 
search of proper bolus compositions and rates, observations on the 
characteristics of several potential matrixes were noted. 
In an effort to ascertain the feasibility of formulating a 
high-density long-termed sustained-release oxytetracycline bolus for 
use in bovine that would effectively deliver a desired therapeutic 
11 
dose over a 45-60 day period, 45 g boluses were prepared of 9 g 
oxytetracycline blended in 36 g matrix (i.e. 20 percent oxytetracycline 
bolus). Five boluses were made of each of the matrix formulations 
I-III in Table I. The boluses were pressed at ca 562.46 kg/cm2 and 
administered to 5 fistulated heifers. Bolus degradation was monitored 
post-administration as described in general procedures. 
Increasing Binding Properties 
Based upon the results of varying the matrix compositions, it was 
felt that the bolus release rates could be improved to provide a less 
variable and more consistent delivery of oxytetracycline. Also, there 
was an obvious need to improve on the longevity of the boluses since 
those in the previous study did not last for a sufficient length of 
time. From previous testing dealing with bolus formulation, it was 
noted that variability and inconsistency in release rates could be 
kept to a minimum by 2 methods. First of all, an increase in pressure 
will enhance particle binding and give a more controlled release of 
drug. Secondly, a decrease in the amount of PEG was thought to aid in 
the binding of particles within the bolus thereby, providing a longer 
lasting and more controlled-release of drug. A second experiment was 
Matrix 
TABLE I 
MATRIX COMPOSITIONS TESTED FOR DEVELOPMENT OF 
SUSTAINED-RELEASE OXYTETRACYCLINE BOLUSES 
Percentage Matrix Com~osition 
Barium 
12 
Number Carnauba Sulfate Polyethyleneglycol 
I 23.6 68.0 8.2 
II (A) 27.3 63.6 9. l 
II (B) 27.3 68.2 4.5 
I II 20.0 60.0 20.0 
IV 28.3 70. l 0.9 
v 28.0 70. l l. 9 
VI 27.8 69.4 2.8 
VII 27.5 68.8 3.7 
-----------
begun to a 11 evi ate the problems of excessive variability in rel ease 
rates and the short life of the boluses. In this study, the matrix 
showing the most promising potential for sustained-release formulation 
was utilized (Matrix II). Four 20 percent oxytetracycline boluses 
were prepared using candidate Matrix II and administered to 4 fistulated 
heifers. Pressure applied to these boluses was increased to ca 632.77 
kg/cm2 compared with that used in previous studies. This should 
provide an increase in the binding of the components and give a more 
consistent release of oxytetracycline. Consequently, these boluses 
were labeled as Matrix II (A). Four 20 percent boluses were also 
prepared from Matrix II (B) which was a slight modification in Matrix 
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II (A). In this trial a lesser amount of polymer was used. Based upon 
results of the previous study, it was felt that this decrease in PEG 
would provide a stronger binding effect in the boluses thereby giving 
a more uniform and less variable release of oxytetracycline. These 
boluses were pressed at ca 681.98 kg/cm2 and administered to 4 fistu-
lated heifers. Bolus degradation was evaluated post-administration as 
described in general procedures. 
Varying PEG Concentrations 
The successful ability of Matrix II to handle oxytetracycline 
prompted the design of a study to determine the effect of varying the 
amount of PEG loaded into Matrix II. It was believed that the amount 
of PEG present affects the binding of the particles. The lesser the 
amount of polymer the stronger the binding effect and therefore, a 
more controlled-realse of drug. Twenty percent oxytetracycline 
boluses formulated with Matrix II and varying amounts of PEG were 
prepared and administered to the fistulated heifers. In this test, 
increasing increments of PEG ranged from 0.9-3.7 percent and 4 boluses 
of each formulation (Matrix IV-VII; Table I) were produced and admin-
istered to 5 fistulated heifers. Post-administration evaluation was 
monitored as described in general procedures. 
Therapeutic Drug Quantities 
Evaluation of data from earlier experiments illustrated that 
oxytetracycline could be formulated in a sustained-release system and 
that therapeutic dosages could be maintained. In order to develop 
sustained-release formulations for use in regimens which are applicable 
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in difficult management situations, it was necessary to determine the 
maximum amount of oxytetracycline that could be utilized in Matrix Il. 
By knowing this, it would provide the greatest amount of drug to the 
animal, thereby enhancing the effect of treatment and possibly reducing 
the length and number of treatments needed. An experiment was designed 
using 45 g boluses formulated with 5 concentrations of oxytetracycline 
(14, 15, 17, 20 and 25 percent). Five boluses of each concentration 
were prepared and administered to 8 fistulated heifers. Post-
administration bolus degradation was monitored as described in general 
procedures. 
Commercial Preparatf9_11~ 
In ascertaining feasibility of formulating a sustained-release 
oxytetracycline bolus by utilizing candidate matrixes, various composi-
tions, and pressures, the potential of the phenomena of controlled-
release via bolus formulations prompted several leading pharmaceutical 
companies to express an interest in this technology. Commercial 
production requires certain refinements in order to attain compositions 
suitable for commercial tableting machines. After reviewing descrip-
tions of industrial punches and dies, and evaluating the circumstances 
under which these boluses would be produced, additional studies were 
designed. Since difficulty was anticipated in force pressing the 
boluses from industrial single punch presses, recommendations call for 
the addition of a lubricant to enhance the flow properties of the 
matrixes to prevent restrictions in flow rates. With this in mind, an 
experiment was designed to incorporate varying amounts ofthe lubricant, 
magnesium stearate, into the final formulation. In this study, 20 
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percent oxytetracycline boluses were formulated with Matrix II and 3 
concentrations of magnesium stearate (0.5, 0.75, and 1.0 percent) was 
blended into the final formulation. Five boluses of each concentration 
were prepared and administered to 5 fistulated heifers. Bolus erosion 
was monitored as described in general procedures. 
It was also recommended that a study be designed to utilize 4 
different pharmaceutical grades of carnauba wax to determine which 
grade closely represented that used in previous trials at Oklahoma State 
University. This study involved formulation of 20 percent oxytetra-
cycline boluses with Matrix !I's composition but substituting the 
carnauba with those of the pharmaceutical companies. Previous trials 
at Oklahoma State University utilized the least expensive grade, Type 
4, filtered, supplied by S. C. Johnson and Son, Inc. (Racine, Wisconsin). 
The 4 grades listed in Table II represent those commercially available 
and used. These are of a more refined nature and represent a higher 
quality of carnauba. In testing these grades of carnauba, four 20 
percent boluses of each grade were prepared. Magnesium stearate was 
added to the final formulation at 0.5 percent and pressed at ca 681.98 
kg/cm2. Boluses were then administered to 6 fistulated heifers to 
determine the effects. Following administration, boluses were evaluated 
as described in general procedures. 
Results and Discussion 
Vay-li.D_9_llatri x Composition~_ 
Data recorded during initial efforts to ascertain the feasibility 
of formulating a sustained-release osytetracycline bolus indicated that 
TABLE II 
PHARMACEUTICAL GRADE CARNAUBA WAXES TESTED 
FOR COMMERCIAL APPLICATION 
Carnauba Grade 
Carnauba Wax N.C. #3 Brazilian Refined Flakes 
(Light) Ross 
Carnauba Wax N.C. #3 Brazilian Refined Flakes 
(Dark) 
Carnauba Wax N.C. #3 Pure American Refined 
Flakes 
Carnauba Wax Ross Refined #3 N.C. Light Flakes 
the controlled-release of oxytetracycline from an inert matrix 
within the bovine rumen could be achieved. Figure l shows the 
estimated daily release rates of the 20 percent oxytetracycline 
boluses from Matrix I. These boluses were discovered broken in half 
on day 15. They were found to be short-lived (i.e. 21 days) and 
therefore, considered inferior as a potential binder with oxytetra-
cycline. The 20 percent oxytetracycline boluses prepared from Matrix 
II (Figure 2) produced a durable composition. Boluses of this nature 
had a density of ca 1.85 g/cm3 which was sufficient to prevent 
passage or regurgitation from the rumen. The release rates climbed 
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steadily for the first 25 days with a mean release of 137 mg/bolus/day. 
After this period, the .release rates dropped sharply. Between days 25 
and 39 the release rates deviated from bolus to bolus by ca 20-30 
mg/bolus. It appeared that the proper components and rates of each 
Figure l. Release of Oxytetracycline Through 
In-vivo Degradation of 20 Percent 
Oxytetracycline Boluses Prepared 
From Matrix I 
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Figure 2. Release of Oxytetracycline Through 
In-vivo Degradation of 20 Percent 
Oxytetracycline Boluses Prepared 
From Matrix II 
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were present, but the formulation was lacking sufficient pressure to 
provide a consistent release rate of oxytetracycline. The test lasted 
for 39 days and had a mean release rate of 129 mg/bolus/day .. Boluses 
21 
of Matrix III developed a surface that was eroding in large layers. 
These boluses were found to be weaker in structure due to insufficient 
amounts of binder to hold the particles together. On the 4th day of 
inspection all boluses had broken into 6 pieces and were also considered 
inferior as a candidate matrix. 
Increasing Binding Properties 
The suitability of the 20 percent oxytetracycline boluses from 
Matrix II received further in-vivo testing to provide a stronger binding 
effect. Figure 3 shows the estimated daily release rates of the 20 
percent boluses of Matrix II (A) and Matrix II (B). Boluses of Matrix 
II (A) were consistent in eroding at a rate of 162 mg/bolus/day for the 
first 35 days. After this period, release rates became irregular due 
to an incidence of bolus breakage within the rumen. This problem was 
due to a level of PEG that was not conducive for adequate bolus tensile 
strength. Consequently, this breakage of boluses caused a substantial 
increase in surface area of the boluses and thus, the release rates 
were influenced. Although these boluses broke in half, between days 
8-46 the average daily release remained between 120 and 220 mg/bolus. 
The 20 percent oxytetracycline boluses for~ulated from Matrix 
II (B) followed the same general erosion pattern as those previously 
described. These boluses maintained a mean release of over 150 mg/ 
bolus/day between days 11-55. A sandstone-like bolus surface developed 
and all boluses eroded evenly throughout the test. The average daily 
Figure 3. Degradation of 20 Percent Oxytetracycline, 
Matrix II Boluses 
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release rate up to the tennination of the study on day 55 was 162 
mg/bolus/day. In comparing the amount of PEG and the increased 
pressure used in the matrix, it was noted that the lesser amount of 
PEG provided the uniformity necessary for a consistent release of 
oxytetracycline, while the 226.8 kg increase in pressure appeared to 
provide the proper binding of particles within the bolus. Resulting 
properties due tG this decreased amount of PEG and the increased 
pressure included a more consistent and uniform release of drug, an 
increase in bolus lengevity by ca 10 days and most important, the 
arrestment of bolus breakage within the rumen. 
Varying PEG Concentrations 
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In this study of varying the percent PEG, PEG added at rates of 
0.9, 1.9, 2.8, and 3.7 percent illustrated a direct relationship 
between the polymer and its concentration in the bplus. PEG added at 
0.9 percent (Figure 4) provided a relatively stable release of 
oxytetracycline for the life of the bolus (67 days) with an average of 
126.3 mg/bolus/day. At 1.9 percent (Figure 5) bolus degradation 
increased to 143 mg/bolus/day, a difference of ca 17 mg/bolus/day over 
the 0.9 percent concentration. In addition, this higher release rate 
caused a shortening in bolus longevity by 17 days. These boluses ter-
minated at day 50. In Figure 6, the 2.8 percent PEG composition 
provided an average daily release of 173.5 mg/bolus for 50 days. This 
bolus eroded with the same general pattern as those of the 1.9 percent 
composition but a difference of ca 30.5 mg/bolus/day was observed. 
Boluses of the 3.7 percent PEG composition appeared to be eroding at 
a much lower level than normally seen (i.e. 75 mg/bolus/day) during the 
Figure 4. Degradation Analysis of 20 Percent 
Matrix IV Boluses With 0.9 
Percent PEG 
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Figure 5. Degradation Analysis of 20 Percent 
Matrix V Boluses With 1.9 
Percent PEG 
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Figure 6. Degradation Analysis of 20 Percent 
Matrix VI Boluses With 2.8 
Percent PEG 
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first 18 days (Figure 7). After this period, release rates increased 
to 178 mg/bolus/day. Also, the bolus surfaces were sluffing minute 
chips suggesting incompatibility and consequently, contributing to the 
daily variability noted during this test period. 
As a result of varying the PEG concentration, PEG was considered 
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to be the most advantageous additive to facilitate bolus erosion. The 
release rates were found to be proportional to the amount of PEG 
present in the bolus. Also, it was noted that the day to day variation 
increased as the amount of PEG increased, and bolus longevity decreased 
as the PEG concentration increased. 
Therapeutic Drug Quantities 
Up to this point, data has indiaated that oxytetracycline can be 
formulated for delivery in a sustained-release system and that 
therapeutic dosages can be maintained. Further in-vivo testing to 
determine the highest therapeutic drug level that could be offered to 
the animal and still remain compatible with the present compositio~ 
illustrated that oxytetracycline blended at 14, 15, 17, 20 and 25 
percent rates yielded several important findings. The release rates 
given in Figure 8 illustrated the significant trend in differences 
between the 14, 5, 17, 20 and 25 percent oxytetracycline boluses. As 
I 
the amount of active ingredient increased, the bolus release rates also 
increased but were followed by a shortening in longevity. The 14 
percent boluses eroded uniformly throughout the test period. During 
the first 20 days, bolus release rates never rose above 45 mg/bolus/day. 
Only the last 3 inspection days did release rates exceed 40 mg/bolus/ 
day. Consequently, the trial was terminated on day 42 although there 
Figure 7. Degradation Analysis of 20 Percent 
Matrix VII Boluses With 3.7 
Percent PEG 
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Figure 8. Comparison of Various Oxytetracycline 
Concentrations in a 45 g Bolus 
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was sufficient material to last 25-35 additional days. The 15 percent 
boluses for the first 19 days had a mean release of 54 mg/bolus/day. 
During days 19-58 the mean release rate increased to 110 mg/bolus/day. 
As the boluses approached the weight of 5 g, the boluses bagan to chip 
and break in half. It. was believed that bolus tensile strength was 
greatly decreased as the boluses became smaller in both size and weight. 
After such occurrences, broken boluses were found to influence the 
release rates greatly. The 17 percent boluses responded to the 
increased amount of oxytetracycline as was seen by a mean release of 
123 mg/bolus/day for the first 51 days. After this period, release 
rates slowed down to yield a mean release of 110 mg/bolus/day for the 
72 day study. Release rates recorded from the 20 percent oxytetra-
cycline boluses had a mean release of 163 mg/bolus/day for the first 
34 days. This increase in oxytetracycline delivery supported the 
assumption that an increase in the amount of active ingredient results 
in higher degradation and release rates since less binder is present 
in the formulation to hold the active ingredient (Table III). This 
study continued for 62 days with a mean release of 152 mg/bolus/day, 
a difference of 42 mg from the 15 and 17 percent boluses. The highest 
release rates were recorded from the 25 percent oxytetracycline boluses 
which had a mean release of 185 mg/bolus/day for the 42 day test period. 
Throughout the trial, release rates exceeded normal variability. This 
was due to a high level of oxytetracycline which was not conducive for 
proper particle binding. Also, the excessive variability noted from 
bolus to bolus was thought to be due to the fact that the boluses 
began to break in half at day 21. As they broke, the surface area 
of the bolus was increased and thereby ca,used an increase in bolus 
degrqdation. 
TABLE III 
RELEASE RATES OF INCREASING PERCENTAGES OF 
OXYTETRACYCLINE IN A 45 g BOLUS 
PREPARED FROM MATRIX ll . 
Percentage 
Oxytetracycli ne 
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Mean 
Daily Release 
in Bolus Composition (mg) Over Test Period 
14 31. 3 
15 110. 0 
17 110. 5 
20 152. 6 
25 184. 5 
In summarizing the data collected in this study, it was noted that 
the sustained-release of therapeutic drug levels could be achieved and 
theoretical bolus release rates were proportional to the amount of 
oxytetracycline present. The average daily release rates in this study 
were slightly above normal variability. Such variation could be 
attributed to animal variation in rumen content. Occasionally, fistu-
lated animals would retain a more fluid filled rumen while others 
maintained the stratified layers (Smith et al. 1955) with various 
percentages of dry matter feed. Another factor contributing to the 
variability was the fact that location of individual boluses within the 
rumen influenced release rates. Those located in the reticulum had 
slightly higher release rates than those found in the ventral sac. 
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Commercial Preparation 
The most promising ingredients providing the greatest compatibility 
and longevity were selected for commercial production testing. This 
studj involved the addition of a lubricant (magnesium stearate) at 
rates of 0.5, 0.75, and 1.0 percent (Figures 9 and 10). Boluses 
formulated without any magnesium stearate proved to be more durable 
than those utilizing magnesium stearate. These bolus release rates 
remained between 105 and 130 mg/bolus/day during days 7 through 55. 
For the 60 day test period the mean oxytetracycline release rate was 
112.5 mg/bolus/day. Oxytetracycline boluses with 0.5 percent magnesium 
stearate were less durable than those without magnesium stearate. 
These boluses followed a general pattern similar to the 0.0 percent 
boluses. Although the mean daily release of oxytetracycline remained 
at or above 100 mg/bolus during days 7 through 60, these release rates 
had a greater variability throughout the study. A mean release rate 
of 110.4 mg/bolus/day was recorded during the 60 day test period. The 
bolus with 0.75 percent magnesium stearate also remained between 100-
121 mg/bolus/day for the entire 50 day study. Only the first inspection 
day had a release rate below 100 mg (95 mg). This formulation had a 
very consistent and uniform oxytetracycline delivery. Boluses eroded 
evenly during the test period with the exception that longitudinal 
cracks began to develop at the latter part of the test. For this 
reason, boluses were removed although they·did not break apart. A 
mean release rate of 111.6 mg/bolus/day was observed. Those boluses 
containing the highest percent of magnesium stearate (l percent) had 
a less durable composition than those just mentioned. A mean release 
Figure 9. Analysis of a 0.5 Percent Magnesium 
Stearate Concentration in 20 
Percent Oxytetracycline Boluses 
Prepared From Matrix II 
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Figure 10. Analysis of a 0.75 and 1.0 Percent 
Magnesium Stearate Concentration 
in 20 Percent Oxytetracycline 
Boluses Prepared From Matrix II 
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of oxytetracycline at 104 mg/bolus/day was recorded for the 50 day test 
period but, release rates exceeded normal variability. The magnesium 
stearate appeared to influence tensile strength at the l percent level. 
Longitudinal cracks developed on day 27 and continued to expand even 
though boluses did not break in half. 
Data from this study indicated that the lubricant magnesium 
stearate influenced oxytetracycline delivery. It was noted that the 
higher the concentration of magnesium stearate, the more variation 
seen in average daily release rates. Also theoretical release rates 
were found to decrease slightly as the magnesium stearate concentra-
tion increased. Based upon these results, the level of magnesium 
stearate most compatible with this formulation appeared to be the 0.75 
percent level. 
The 4 pharmaceutical grade carnauba waxes listed in Table II were 
screened for compatibility with oxytetracycline. During this study, 
all boluses were found to be eroding uniformly throughout the study. 
Termination of the study was initiated after 45 days although boluses 
were not completely degraded. This was done due to additional needs 
for these animals. Figure 11 shows that the 20 percent oxytetracycline 
boluses of the Brazilian Refined Flakes (light) Ross, eroded evenly 
with a mean daily release of 113.0 mg/bolus for the first 32 days. 
After this period, the release rates rose to 116.5 mg/bolus/day. For 
the entire 45 day test period, a mean release of 113.4 mg/bolus/day 
was recorded; 
Boluses of the Brazilian Refined Flakes (dark) (Figure 12) were 
found to have a mean release of 103.3 mg/bolus/day for the first 32 
days. This difference observed from the previous boluses was due to 
Figure 11. Release of 20 Percent Oxytetracycline 
Boluses Utilizing Brazilian Refined 
Flakes (Light) Ross Carnauba Wax 
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Figure 12. Release of 20 Percent Oxytetracycline 
Boluses Utilizing Brazilian Refined 
Flakes (Dark) Carnauba Wax 
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the lower release of drug for the first 3 inspection days. After this 
acclimation period to the rumen, boluses began to erode quicker with a 
mean release of 127.6 mg/bolus/day during days 14-46. The mean release 
rate for the test period was 111.0 mg/bolus/day. The highest release 
rates were recorded by the 20 percent oxytetracycline boluses from the 
Pure American Refined Flakes. Only on the first day of inspection were 
the mean release rates below 100 mg/bolus. Figure 13 shows that between 
days 7-46, a mean daily release of 130 mg/bolus/day was observed. These 
boluses exhibited a greater variation in bolus to bolus release rate 
than those afore mentioned. The 45 day test period had a mean release 
of 123.4 mg/bolus/day. Those boluses produced from the Ross Refined 
#3 light flakes (Figure 14) closely resembled those of the Brazilian 
Refined Flakes. A slow eroding bolus was noted for the first 3 
inspection days. After this period, the release rates were extremely 
consistent. From days 14.46, a mean release of 124.6 mg/bolus/day 
was recorded. This trial had a mean release of 103 mg/bolus/day for 
the 46 day test period. 
In summarizing this study, it was noted that mean release rates 
of 103.0-123.4 mg/bolus were recorded. These 4 pharmaceutical grades 
of carnauba wax proved to be similar to each other since only 20-23. 
mg difference was observed when comparing them. The significance seen 
in this study was that 2 of the grades had a slower release rate for 
the first 14 days, after which all carnauba grades appeared equal. 
In summary, the data recorded during the development of a 
sustained-release oxytetracycline bolus indicated several important 
findings. Initial efforts of development indicated that the proper 
bo 1 us crn11ponents and rates of each were essenti a 1 for successful 
Figure 13. Release of 20 Percent Oxytetracycline 
Boluses Utilizing Pure American 
Refined Flakes Carauba Wax 
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Figure 14. Release of 20 Percent Oxytetracycline 
Boluses Utilizing Ross Refined #3 
Light Flakes Carnauba Wax 
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controlled-release systems. Sufficient amounts of binder, compression 
and PEG were needed to achieve a consistent and uniform release of 
oxytetracycline. It was also found that the most advantageous 
component to facilitate bolus degradation was PEG. As the percentage 
of PEG increased, the oxytetracycline release rates also increased. 
Along with the PEG, the theoretical release rates were found to be 
proportional to the amount of oxytetracycline present. In order to 
attain a product for commercial consideration, it was noted that the 
lubricant magnesium stearate at the 0.5-0.75 percent level was the 
optimum level necessary for commercial production. 
Also, the 4 pharmaceutical grades of carnauba were found to be 
similar in comparison. Since commercial production would require the 
utilization of one of these waxes, minor refinements may be necessary 
to achieve a slightly higher release of oxytetracycline. 
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Based upon these results, it was noted that oxytetracycline could 
be offered to ruminants at a controlled release for an extended period 
of time. Also, data illustrated that therapeutic drug levels could be 
achieved and maintained. Although minor refinements may be necessary 
to produce a commercially available oxytetracycline bolus, the 
potential of the sustained-release oxytetracycline bolus has been 
demonstrated and therefore, encourages further testing to determine its 
efficacy agains·t vector-borne anaplasmosis. 
CHAPTER III 
BIO-ASSAY FOR EFFICACY AGAINST 
VECTOR-BORNE ANAPLASMOSIS 
Previous data collected from 20 percent oxytetracycline boluses 
prepared from an inert matrix containing carnauba wax, barium sulfate 
and PEG (Chapter II) indicated the provision of oxytetracycline at ca 
160 mg/bolus/day for 50-60 days. Previous workers reporting on tetra-
cycline treatments administered orally and via injections have indi-
cated that low-level dosages of the drugs for extended periods of 
time would provide successful anaplasmosis control to bovine (Pearson 
et al. 1957). From a developmental standpoint, an efficacy trial was 
necessary to determine whether therapeutic blood levels could be main-
tained by a sustained-release bolus formulation. Such bio-assay data 
would credit this new treatment regimen and provide valuable information 
to further refine and develop the oxytetracycline bolus. The purpose 
of the following studies was to determine the efficacy of various drug 
levels in the prevention of anaplasmosis transmission by infective 
ticks frequenting cattle and to determine the potential of the oxytetra-
cycline bolus against carrier infections. 
Methods and Materials 
Experimental animals consisted of Holstein and Jersey dairy cows, 
4- 7 years of age, which were purchased from an anaplasmosis-free dairy 
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herd. Prior to exposing the animals to the disease, hematocrits and 
compliment-fixation (CF) tests were conducted to determine whether the 
packed cell volumes (PCV) were within the usual range and that there 
was no serologic evidence of previous exposure to anaplasmosis. 
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To obtain anaplasmosis infective ticks for disease transmission, 
Dermacentor andersoni Stiles nymphs were reared and maintained at the 
Oklahoma State University Entomology Tick Laboratory. To serve as an 
infective blood source _for the laboratory reared nymphal ticks, a 
splenectomized yearling Holstein calf was inoculated intrave~ously with 
a Virginia isolate of~· marginale. These nymphs were placed on the 
infected calf at a parasitemia of 1 percent. As tick feeding takes 
7-14 days, the rapid stage of tick feeding was anticipated to coincide 
with the increasing parasitemia normally seen 10-12 days post-exposure. 
After development to the adult stage, the ticks were utilized for 
disease transmission studies. 
Prior to drug therapy, the cattle were divided into several groups 
with 1 group designated as nonmedicated controls and the others 
designated as treatments. Animals were weighed 3 times prior to 
bolus treatment to determine the proper dosage of drug for each animal. 
All animals were then placed in cattle stanchions and maintained on a 
cotton-seed hull based ration to minimize gain during the test period. 
After the adult ticks had completed engorgement, animals were returned 
to the dry-lot area. Oxytetracycline treatment was administered via 
20 percent boluses at the beginning of the test period (day 0). On 
day 10 all groups were challenged for disease transmission by exposing 
each animal to A. marginale by feeding infective D. andersoni ticks on 
these susceptible animals. Disease challenge was initiated on day 10 
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since therapeutic blood levels were reached after boluses had been 
in the rumen for 7-10 days. Each animal was infested with 75 pair of 
the adult D. andersoni ticks. Following exposure to the causal agent 
(day 10), the status of each animal was evaluated 3 times each week 
until the first sign of infection was noted. After which, daily blood 
samples were collected for evaluation by Wright 1 s stained blood slides, 
PCV, and CF test. 
Drug efficacy was ascertained by evaluating the PCV, CF test, 
and parasitemia values at each sampling to determine the influence 
of treatment on the ability to prevent disease transmission~ Those 
animals found to beeither negative or suspicious for the disease were 
subjected to further evaluation procedures by sub-inoculation of the 
treated animals blood into a splenectomized calf (Jones 1968). This 
calf was then evaluated by utilizing the previously mentioned hema-
tologic and serologic techniques for detection of the disease. 
Disease Transmission Studies 
In initial testing to determine the effects of various oxytetra-
cycline drug levels in the ability to prevent disease transmission by 
infective ticks, testing began to establish definite levels of anti-
biotic dosages for. prevention of anaplasmosis transmission. Cattle 
were divided into 4 groups as shown in Table V. Group I was designated 
as nonmedicated controls. Oxytetracycline was administered to Groups 
II, III, and IV at a dosage of 0.23, 0.32, and 0.45 mg/kg of body 
weight (b.w.) respectively on day 0. After tick challenge on day 10, 
hematologic and serologi_c techniques previously described were 
conducted for drug-efficacy evaluation. 
Data recorded during this preliminary trial indicated that the 
oxytetracycline level was not adequate to prevent anaplasmosis trans-
mission. Therefore, a second study was designed to determine the 
drug range limits which would prevent disease transmission. In this 
study, the above mentioned procedures were utilized with the exception 
that oxytetracycline was administered at 0.35 and 1.0 mg/kg b.w. since 
Franklin et al. (1967) reported that 0.5-1.0 mg/kg would eliminate 
anaplasmosis infections. 
In summarizing the data obtained during the 2 previous trials it 
was indicated that although disease transmission was not prevented,. 
the usual prepatent period of the disease was prolonged considerably. 
Since previously used drug levels failed to prevent disease trans-
mission, another study was designed using higher drug levels. In this 
trial, 4 groups of animals were utilized (Table IV). Group I were 
nonmedicated controls while Groups II, Ill, and IV were administered 
oxytetracycline at 2.0, 2.5 and_ 3.0 mg/kg respectively. Following 
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drug administration (day 0) and tick challenge (day 10), all animals 
were evaluated using the previously described hematologic and serologic 
techniques. 
Carrier Elimination 
Tetracyclines have been extensively tested for efficacy in 
eliminating anaplasmosis carrier infections (Brock et al. 1958). 
Protection from spreading of the disease is needed during the insect 
vector season since anaplasmosis transmission can occur from carrier 
animals and therefore infect the entire herd. It was necessary that 
the efficacy afforded by the continuous-release of oxytetracycline to 
TABLE IV 
DRUG THERAPY DESIGN FOR EVALUATING SUSTAINED-RELEASE 
OXYTETRACYCLINE BOLUS AGAINST 
ANAPLASMOSIS TRANSMISSION 
Oxytetracycl i ne 
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Mean 
Cattle 
Group Dosage Weight (kg) 
I Non- Medi ca ted Control 749.3 
I I 2.0 mg/kg 671.0 
III 2.5 mg/kg 589.6 
IV 3.0 mg/kg 565.0 
carier cattle on pasture be determined therefore, early pilot studies 
were designed to establish the proper dosage of oxytetracycline for 
removal of carrier infections in cattle. 
Seven Holstein, Aeryshire and Jersey dairy cattle which were 
carriers of anaplasmosis and whose carrier status was determined by a 
history of disease attack as well as repeated positive reactions to the 
CF test, were divided into 4 groups with 1 group serving as a control. 
·Treatment groups (I, II, and III) were comprised of 2 ani·mals per 
group while Group IV was a nonmedicated control group. Oxytetracycl ine 
was administered at a rate of 1.0 mg/kg b.w. to Group I. Groups II 
and III were given oxytetracycline at a dosage of 1.5 and 2.0 mg/kg b.w. 
respectively. Animals were bolused accordingly with a 20 percent 
oxytetracycline bolus. Blood was collected weekly from each animal 
and success or failure of treatments were determined by a CF test and 
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the subinoculation of treated animals' blood into splenectomized calves 
when the CF test warranted. After 60 days if no positive results were 
recorded, animals were rebolused for an additional 60 days. 
In subsequent testing, 15 Hereford and Angus cattle determined 
carriers by CF test were acquired for experimental use. These animals 
were maintained on 160 acres of native pastureland located in Payne 
County, Oklahoma. Animals were weighed 3 times prior to drug therapy 
to detern1ine the proper bolus treatment. Previous studies implied 
that a minimum drug level of 1.5 mg/kg b.w. was required. Therefore, 
these animals were divided into 5 groups as shown in Table VIII. With 
3 animals in each group, Groups I, II, III and IV received oxytetra-
cycline at a rate of 1.5, 2.0, 2.5 and 3.0 mg/kg b.w. respectively. 
Due to the fact that the 20 percent oxytetracycline bolus had a 
longevity of 60 days, additional bolusing was administered at the end 
of this period in order to provide a 120 day treatment. Group V 
was designated as nonmedicated controls. After animals were bolused 
accordingly, blood s~mples were collected on a weekly basis for 
evaluation using CF test. Following the 120 day bolus treatment, 
animals were held for an additional 60 days in order to allow for 
complete clearance of any oxytetracycline residues which may occur 
within the animals' tissues. After this period, 2 animals of each 
group determined negative or suspicious of anaplasmosis infection were 
prepared for subinoculation procedures. One hundred seventy-five mls 
of blood from 2 animals in each group were pooled and treated with 
neoarsphenamine as described by Jones et al. (1968). The blood was 
treated with this drug since the epirythrizoan complex is usually 
associated with anaplasmosis infections and thereby making it harder 
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for identification of the anaplasma bodies. This blood was refrigerated 
for 24 hours at 5°c before being injected into the splenectomized 
Hereford calves. PCV, parasitemia values and CF test were conducted 
on a daily basis to determine results. 
Results and Discussion 
Disease Transmission 
Data recorded during disease transmission studies indicated that 
the animal serving as a source of infective blood for infection of 
D. andersoni nymphs reached a peak parasitemia of 48 percent. Since 
tick feeding occurred during this period, it appeared that a highly 
virulent infection was obtained for disease transmission via ticks. 
Initial testing to establish definite levels of oxytetracycline 
dosages for prevention of anaplasmosis transmission, indicated that 
dosages of 0.23, 0.32 and 0.45 mg/kg were not sufficient to prevent 
disease transmission. The influence of treatment on the developing 
parasitemia is shown in Table V. The control group (Group I) showed 
a maximum parasitemia of 13 percent with onset occurring during the 
normal 20-24 day prepatent period. This parasitemia was greater than 
that observed among Groups II and IV. Group II had the lowest 
parasitemia of any treated groups but the dosage of oxytetracycline was 
not the highest level administered. This was thought to be due to the 
animals ability to regenerate red blood cells and thereby, warding 
off the virulence of the infection. It took 58 days for onset of the 
disease to occur in Group IV which had the highest level of drug. 
This prolongation in the prepatent period was due to the inhibitory 
TABLE V 
INFLUENCE OF OXYTETRACYCLINE TREATMENT 
AGAINST ANAPLASMOSIS TRANSMISSION 
BY INEFFECTIVE TICKS 
Packed Cell Volume {PCV~ 
Mean 
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Parasitemia 
Cattle Preinfection Minimum Maximum Pre patent 
Groups Value Percent Percent Period 
I (Control) 35 14.0 13.0 23 
I I (. 23 mg/ kg) 39 28.5 l.8 38 
III (.32 mg/kg 34 19. 5 16.4 57 
IV (.45 mg/kg) 32 21. 0 3.8 58 
effects that the antibiotic has on the anaplasma organism. All animals 
converted to a positive CF titer. At no time did any of the treated 
animals appear critically ill. Constipation was noted in Groups I 
and III. Oxytetracycline treatment in Groups II and IV were effective 
in preventing and reducing clinical signs of the disease such as consti-
pation, inappetence, and dehydration. 
The use of anaplasmosis infected ticks appeared to produce a, 
highly virulent infection as was noted by a rapid reduction in PCV in 
Groups I and III once onset occurred. Compared with the control group, 
response to oxytetracycline therapy by treated Groups II and IV 
indicated that the severity of the infection was greatly reduced. 
Since previous testing illustrated that oxytetracycline levels 
were not sufficient to prevent disease transmission, a dosage range of 
0.30 and 1.0 mg/kg b.w. was used to determine the level of drug that 
would prevent transmission. Results illustrated that disease trans-
mission occurred at this range. All animals converted to a positive 
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CF titer at an average of 42 days post-exposure. A comparison of drug 
efficacy is shown in Figure 15 by the PCV values. The severity of the 
disease was characterized in the control group by a minimum PCV of 18.5 
percent. For the 0.3 mg treatment group a maximum parasitemia value of 
6.1 percent was recorded with a minimum PCV of 16.5 percent. The 1.0 
mg treatment group had a maximum paras1temia of only 0.2 ·percent while 
the minimum PCV was 24.5 percent. Even though disease transmission 
was not prevented, the infectivity level was reduced substantially. 
More importantly, is the fact that clinical disease was prevented 
with the 1.0 mg level since the parasitemia never reached l percent. 
Again, oxytetracycline demonstrated its inhibitory effect on the causal 
agent. 
Data for studies reported herein indicated that clinical 
anaplasmosis could be prevented with a dosage of 1.0 mg/kg. Although 
previous drug levels proved inadequate in preventing disease trans-
mission, data indicated that a slightly higher level would prevent 
transmission therefore, the dosage was increased (2.0, 2.5 and 3.0 mg/ 
kg) and response to oxytetracycline therapy is shown in Table VI. In 
this study the virulence of the infection was characterized by a 
minimum PCV of 12.5 percent while a maximum parasitemia of 20.6 
percent was noted in the Control group. The variation of parasitemia 
in each of the 4 groups was significant. The severity of the infection 
.recorded coincided with the administration of the higher dosage of 
oxytetracycline. The significance in this study was that disease 
Figure 15. Packed Cell Volume of Cattle Treated 
With 20 Percent Oxytetracycline 
Boluses 
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TABLE VI 
RESPONSE OF OXYTETRACYCLINE BOLUS THERAPY AGAINST 
DISEASE TRANSMISSION BY INFECTIVE TICKS 
Packed Cell Volume (PCV} Parasitemia 
Mean 
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Cattle Preinfection Minimum Maximum Prepatent 
Groups Value Percent Percent Period 
I (Control) 32 12.5 20.6 30 
II (2.0 mg/kg) 37 22.0 5.2 31 
III (2.5mg/kg) 36 30.5 0.4 44 
IV (3.0 mg/kg) 34 24.0* 0.0 
* Low PCV due to severe case of mastitis 
transmission was prevented in Group IV at a dosage of 3.0 mg/kg b.w. 
as was determined by blood slides and CF tests. This animal did have 
a lowered PCF {24 percent) which was due to development of a severe 
case of mastitis. This animal was severely affected by this infection 
but no treatment was administered since the animal was still on study. 
After 58 days post-exposure to anaplasmosis and prior to subinoculation 
procedures this animal died due to the mastitis infection. Treatment 
at all 3 levels demonstrated some effectiveness when compared with the 
nonmedicated controls. Based on the influence of oxytetracycline 
therapy on PCV and parasitemia, a pattern of effectiveness from each 
dosage was observed. The severity of infection was reduced in Groups 
II and III with only the subclinical disease occurring in Group III. 
This trial illustrated that the oxytetracycline bolus has the potential 
to prevent disease transmission by infective ticks and to prevent 
clinical anaplasmosis from occurring. 
Carrier Elimination 
Low levels of tetracyclines have been shown to be effective in 
eliminating the carrier state of anaplasmosis. It was felt that 
treatments via a 20 percent oxytetracycline bolus at 1.0-2.0 mg/kg 
b.w. for 60-120 days would also be effective. In this preliminary 
trial, Table VII summarizes the results. All groups had high serum 
titers at the time treatment was given. CF testing occurred on a 
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weekly basis with titers remaining at 4+ (positive reaction) throughout 
the first 60 day period. Animals were rebolused for another 60 days 
and Group II cattle showed a 2+ and 3+ titer (suspicious reaction) to 
the CF test during the last 30 days of treatment. After 120 days from 
initial bolusing, a splenectomized calf was inoculated with blood from 
Group II animals. This calf developed anaplasmosis after a prepatent 
period of 27 days. Results of this experiment indicated that total 
elimination of the carrier infection was not possible at these dosage 
levels. However, the treatment was obviously bordering the line between 
success and failure. 
Previous testing implied that animal drug levels were above the 
1.5 mg level therefore, efficacy trials for elimination of carrier 
infections continued. Table VIII shows the drug design and the 
influence of treatment on the carrier state. It was anticipated that 
the response to oxytetracycline therapy would be directly related to 
the drug dosage. However, data illustrated that this did not occur. 
TABLE VII 
RESPONSE OF CATTLE TO OXYTETRACYCLINE BOLUS TREATMENTS 
FOR ELIMINATION OF ANAPLASMOSIS CARRIER INFECTIONS 
Mean CF Titer* 
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At Time 120 Days 
Treatment of After 
Group (mg/kg) Dosages Treatment Treatment 
I 1.0 2 160 lOR 
II 1. 5 2 40 < 5S 
II I 2.0 2 160 lOR 
IV control none 80 45R 
* Titers expressed as reciprocal of the highest dilution of sera 
showing fixation of compliment. 
Those animals receiving 1.5 mg oxytetracycline/kg b.w. showed a 
suspicious {3+) CF titer within the first 30 days of treatment. This 
group remained either negative or suspicious throughout the 120 day 
treatment period and remained so for 60 additional days (i.e. 180 
days total). Group II animals exhibited positive reactions to the CF 
test up until the 120 day period, after which 2 animals were observed 
to be suspicious (2+) for the disease. Those animals in Group II, Ill, 
and IV remained positive for anaplasmosis throughout the 180 day test 
period. It was anticipated that the response to oxytetracycline treat-
ment at the higher dosages was influenced by the fact that the number 
of boluses required to deliver this rate to a large animal caused 
release rates to exceed the normal delivery. Studies conducted 
Group 
I 
II 
III 
IV 
v 
TABLE VII I 
DESIGN AND INFLUENCE OF OXYTETRACYCLINE TREATMENT 
ON ANAPLASMOSIS CARRIER INFECTIONS 
CF Titers 
At Time 120 Days 
Weight Dosage of After 
(kg) (mg/kg) Treatment Treatment 
505 1. 5 lOR N 
460 1. 5 20R s 
465 1. 5 lOR N 
474 2.0 5R lOR 
453 2.0 lOR s 
455 2.0 5R s 
460 2.S SR lOR 
483 2.5 40R 40R 
4SS 2.5 SR SR 
383 3.0 5R lOR 
381 3.0 SR 40R 
304 3.0 SR 20R 
471 control lOR lOR 
433 control lOR 20R 
496 control lOR 20R 
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180 Days 
After 
Treatment 
N 
N 
s 
5R 
s 
N 
SR 
20R 
s 
lOR 
1 OR 
20R 
lOR 
5R 
lOR 
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concurrently have indicated that a relationship between the size of 
an animal's rumen and bolus degradation exists (Riner 1980, unpublished 
data). A 400 kg animal dosed at 3.0 mg/kg b.w. required a treatment of 
8 boluses. Previous efforts in developing the oxytetracycline bolus 
were aimed at a 2-6 bolus treatment. As the increased number of 
boluses were used, the closeness in proximity of individual boluses 
caused an increase in release rates. This consequently caused a 
shortening in bolus longevity thereby decreasing the treatment period. 
Also, this large a number of boluses rubbing together within the bovine 
rumen increased the chances for breakage of the bolus. Such occurrences 
were thought to have happened in Groups IV and V. Another possible 
explanation was that the interaction of antibiotics with the anaplasma 
organism caused a false positive CF titer. Other researchers have 
reported that subinoculation of blood from a CF positive animal into 
a splenectomized calf resulted in the splenectomized calf showing no 
signs of the disease. 
Since the CF test remained negative in cattle from Group I 
which later proved to have anaplasma bodies by subinoculation techniques, 
there were indications that the CF test was not truly accurate for 
determining the success of animals treated with antibiotics. The 
splenectomized calf which did not convert to a CF positive titer was 
thought to have an increased resistance to anaplasmosis. The signifi-
cance of this phenomenon is not known. 
In sunmarizing the data collected during this experiment, it was 
noted that the level of the antibiotic maintained in the animal was an 
important factor in successful eradication of the carrier state. This 
trial simulated field situations where· cattle of varying ages and 
varying stages of infection occur. The merits of this treatment 
program were demonstrated by the fact that the positive CF titers were 
slowly reduced to the suspicious or negative status. 
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CHAPTER IV 
SUMMARY 
The purpose of the experiments described in this thesis was to 
develop and evaluate a sustained-release oxytetracyline bolus for 
prophylaxis and control of vector-borne anaplasmosis in bovine. 
Developmental procedures involved the incorporation of oxytetracycline 
into an inert matrix consisting of various ingredients, compositions 
and rates of each. The potentiaJ of the sustained-release bolus was 
determined by comparing each formulation for a predictable and 
controlled-release of drug for an extended period of time. The efficacy 
of the oxytetracycline bolus for prevention of anaplasmosis transmission 
and treatment of carrier animals was evaluated by CF test, Wright's 
stained blood films and PCV. Further evaluation by subinoculation of 
host blood into susceptible splenectomized calves was conducted when 
warranted. 
Data indicated that oxytetracycline could be formulated in a 
sustained-release system to deliver a uniform and consistent release of 
drug for a 45-60 day period and several parameters examined experi-
mentally support the conclusion. Results indicated that the provision 
of ca 160 mg/bolus/day from a 20 percent oxytetracycline bolus main-
tained effective therapeutic levels for 60 days. Furthermore, efficacy 
trials indicated that dosages of oxytetracycline at 0.5-2.5 mg/kg 
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administered 10 days prior to exposure to A. marginale inhibited the 
multiplication of the organism and decreased the level of infectivity. 
This resulted in the prevention of clinical anaplasmosis. It was also 
found that a dosage of oxytetracycline at 3.0 mg/kg prevented disease 
transmission by infective Q. andersoni ticks. 
The treatment of infected carrier animals with dosages of 1.5-3.0 
mg/kg at 60 day intervals decreased and eliminated positive CF titers. 
This suggested that the carrier state was eliminated but confirmation 
of these results by subinoculation procedures indicated that the total 
elimination of the organism was not accomplished. This was thought 
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to be due to some type of interaction of the antibiotic with the causal 
organism resulting in a false positve CF titer dr that the CF test was 
not truly accurate. 
Although current treatment regimens have been shown to prevent 
and control anaplasmosis, the feasibility and practicality of these 
programs have not been demonstrated. The phenomena of a controlled-
release formulation offers an approach to arthropod and disease 
control which could potentially solve many of the problems associated 
with current control methods. By administering an acaricide or 
therapeutic agent via a sustained-release system sufficient to provide 
season-long control to the animal, several advantages could be realized. 
The offering of biologically active compounds only once or twice per 
season would allow producers to save time and labor thereby, resulting 
in a greater economic advantage. Compared to repeated and periodic 
applications as currently used by most treatment regimens, the 
predictable and consistent release of therapeutic levels via a sustained-
release bolus can be maintained for 60 days with only 1 application. 
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The application of a sustained-release formulation as indicated 
by these studies are important in preventing the perpetuation and trans-
mission of the disease. The increasing prevalence of anaplasma 
reactors, the moderate rate of transmission and the possibility of 
introduction of infected cattle by purchase suggest that a treatment 
program for anaplasmosis prophylaxis and control should extend over a 
prolonged period. The use of a sustained-release oxytetracycline bolus 
affords such a treatment and could provide the basis by which the 
control and eradication of the disease could be accomp'.lished. 
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